Peggy Hwang

2.1k total citations
59 papers, 1.1k citations indexed

About

Peggy Hwang is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Peggy Hwang has authored 59 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Hepatology, 30 papers in Epidemiology and 27 papers in Infectious Diseases. Recurrent topics in Peggy Hwang's work include Hepatitis C virus research (46 papers), HIV/AIDS drug development and treatment (25 papers) and Hepatitis B Virus Studies (18 papers). Peggy Hwang is often cited by papers focused on Hepatitis C virus research (46 papers), HIV/AIDS drug development and treatment (25 papers) and Hepatitis B Virus Studies (18 papers). Peggy Hwang collaborates with scholars based in United States, Germany and France. Peggy Hwang's co-authors include Michael Robertson, Janice Wahl, Barbara Haber, Eliav Barr, Eric Lawitz, Edward Gane, Niloufar Mobashery, Richard J. O. Barnard, A Howe and Christophe Hézode and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Peggy Hwang

57 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peggy Hwang United States	19	757	654	319	134	101	59	1.1k
Padaki Nagaraja Rao India	19	507 0.7×	625 1.0×	267 0.8×	73 0.5×	306 3.0×	77	1.1k
Jacob Alexander United States	13	237 0.3×	336 0.5×	107 0.3×	70 0.5×	115 1.1×	19	638
Marcelo Silva Argentina	17	689 0.9×	591 0.9×	61 0.2×	33 0.2×	150 1.5×	48	938
Soon Ho Um South Korea	23	1.1k 1.4×	1.1k 1.7×	63 0.2×	163 1.2×	377 3.7×	68	1.7k
Xavier Causse France	14	614 0.8×	565 0.9×	120 0.4×	39 0.3×	98 1.0×	52	898
Soo Ryang Kim Japan	15	500 0.7×	472 0.7×	65 0.2×	61 0.5×	139 1.4×	87	880
Marie–Pierre Ripault France	20	2.2k 3.0×	2.2k 3.4×	131 0.4×	33 0.2×	91 0.9×	34	2.5k
A. Iacobellis Italy	17	785 1.0×	751 1.1×	29 0.1×	148 1.1×	288 2.9×	44	1.1k
Ingalill Friis–Liby Sweden	10	397 0.5×	1.1k 1.6×	59 0.2×	97 0.7×	448 4.4×	12	1.4k
Koichi Takaguchi Japan	19	941 1.2×	786 1.2×	75 0.2×	135 1.0×	146 1.4×	58	1.1k

Countries citing papers authored by Peggy Hwang

Since Specialization

Citations

This map shows the geographic impact of Peggy Hwang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peggy Hwang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peggy Hwang more than expected).

Fields of papers citing papers by Peggy Hwang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peggy Hwang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peggy Hwang. The network helps show where Peggy Hwang may publish in the future.

Co-authorship network of co-authors of Peggy Hwang

This figure shows the co-authorship network connecting the top 25 collaborators of Peggy Hwang. A scholar is included among the top collaborators of Peggy Hwang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peggy Hwang. Peggy Hwang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alpizar, Sady, José Accini, Duane C. Anderson, et al.. (2023). Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial. Journal of Infection. 87(5). 392–402. 9 indexed citations

Жданов, К. В., Isakov Va, Svetlana Kizhlo, et al.. (2020). <p>Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial</p>. SHILAP Revista de lepidopterología. Volume 12. 61–68. 2 indexed citations

Hézode, C., et al.. (2019). Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy. SHILAP Revista de lepidopterología. 1 indexed citations

Jacobson, Ira M., Fred Poordad, Roberto Firpi-Morell, et al.. (2019). Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study. Clinical and Translational Gastroenterology. 10(4). e00007–e00007. 12 indexed citations

Lee, Youn Jae, Jeong Heo, Do Young Kim, et al.. (2019). An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection. Clinical and Molecular Hepatology. 25(4). 400–407. 8 indexed citations

Serfaty, Lawrence, Ira M. Jacobson, Jürgen K. Rockstroh, et al.. (2018). The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. Journal of Viral Hepatitis. 26(3). 329–336. 9 indexed citations

Zamor, Philippe J., John M. Vierling, Reem Ghalib, et al.. (2018). Elbasvir/Grazoprevir in Black Adults With Hepatitis C Virus Infection: A Pooled Analysis of Phase 2/3 clinical Trials. The American Journal of Gastroenterology. 113(6). 863–871. 2 indexed citations

Zeuzem, Stefan, Lawrence Serfaty, John M. Vierling, et al.. (2018). The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. Journal of Gastroenterology. 53(5). 679–688. 29 indexed citations

Jacobson, Ira M., Eric Lawitz, Paul Y. Kwo, et al.. (2017). Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Gastroenterology. 152(6). 1372–1382.e2. 58 indexed citations

10.

Bruchfeld, Annette, David Roth, Paul Martin, et al.. (2017). Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Gastroenterology & hepatology. 2(8). 585–594. 53 indexed citations

11.

Howe, A, Stuart Black, Stephanie Curry, et al.. (2014). Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection. Clinical Infectious Diseases. 59(12). 1657–1665. 33 indexed citations

12.

Hwang, Peggy, H. Campbell, Julie Strizki, et al.. (2013). 1198 RESISTANCE ANALYSIS OF CIRRHOTIC TREATMENT-EXPERIENCED GENOTYPE 1 PATIENTS IN A STUDY OF MK-7009 IN COMBINATION WITH PEGYLATED INTERFERON/RIBAVIRIN. Journal of Hepatology. 58. S487–S487. 2 indexed citations

13.

Barnard, Richard J. O., Carolyn McHale, Donald J. Graham, et al.. (2013). Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis. Virology. 443(2). 278–284. 18 indexed citations

14.

Lawitz, Eric, Mark Sulkowski, Ira M. Jacobson, et al.. (2013). Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Research. 99(3). 214–220. 26 indexed citations

15.

Manns, Michael P., Edward Gane, M. Rodríguez‐Torres, et al.. (2012). Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study. Hepatology. 56(3). 884–893. 46 indexed citations

16.

Shah, Sukrut, Anne Hermanowski‐Vosatka, Gang Jia, et al.. (2011). Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. Journal of the American Society of Hypertension. 5(3). 166–176. 76 indexed citations

17.

Brass, Eric P., et al.. (2008). Can Consumers Self-Select for Appropriate Use of an Over-the-Counter Statin? The Self Evaluation of Lovastatin to Enhance Cholesterol Treatment Study. The American Journal of Cardiology. 101(10). 1448–1455. 7 indexed citations

18.

Avins, Andrew L., M. Michele Manos, Lynn Ackerson, et al.. (2008). Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease. Drug Safety. 31(4). 325–334. 28 indexed citations

19.

Avins, Andrew L., et al.. (2006). Abstract 4163: Higher Dose Exposure of Lovastatin is Not Associated with Adverse Hepatic Outcomes in Patients with Existing Liver Disease. Circulation. 114(suppl_18). 1 indexed citations

20.

Levy, Paul S., et al.. (2002). BERYLLIUM AND LUNG CANCER: A REANALYSIS OF A NIOSH COHORT MORTALITY STUDY. Inhalation Toxicology. 14(10). 1003–1015. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact